MX9801550A - Uso de muteinas de citocinas de tipo silvestre como inmunogenos. - Google Patents
Uso de muteinas de citocinas de tipo silvestre como inmunogenos.Info
- Publication number
- MX9801550A MX9801550A MX9801550A MX9801550A MX9801550A MX 9801550 A MX9801550 A MX 9801550A MX 9801550 A MX9801550 A MX 9801550A MX 9801550 A MX9801550 A MX 9801550A MX 9801550 A MX9801550 A MX 9801550A
- Authority
- MX
- Mexico
- Prior art keywords
- wild
- type cytokine
- muteins
- immunogens
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Noise Elimination (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen los compuestos farmacéuticos utilizados para tratar o prevenir enfermedades provocadas por la sobreproduccion de una citocina de tipo silvestre, específica, caracterizados por el hecho de que contienen como un principio activo al menos un mutante de esta citocina de tipo silvestre. En su aspecto más amplio, la invencion consiste en el uso de muteinas de una citocina específica de tipo silvestre, que son también antagonistas de receptores de la ultima, como inmunogenos para producir anticuerpos dirigidos contra esta citocina de tipo silvestre y capaces de neutralizarla en esas enfermedades provocadas por su produccion excesiva. La Figura 4 muestra que los anticuerpos desarrollados en ratones transgénicos NSE/hIL-6 inmunizados con una muteina de al interieucina 6 humana, son capaces de reconocer la interleucina 6 de tipo silvestre y de neutralizar su actividad biologica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95RM000589A IT1277926B1 (it) | 1995-09-01 | 1995-09-01 | Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire |
| PCT/IT1996/000164 WO1997009064A1 (en) | 1995-09-01 | 1996-08-22 | Use of muteins of wild-type cytokines as immunogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9801550A true MX9801550A (es) | 1998-05-31 |
Family
ID=11403544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9801550A MX9801550A (es) | 1995-09-01 | 1996-08-22 | Uso de muteinas de citocinas de tipo silvestre como inmunogenos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6706261B1 (es) |
| EP (1) | EP0858345B1 (es) |
| JP (1) | JP3157837B2 (es) |
| KR (1) | KR100279539B1 (es) |
| CN (1) | CN1138562C (es) |
| AT (1) | ATE226446T1 (es) |
| AU (1) | AU703300B2 (es) |
| CA (1) | CA2229045C (es) |
| DE (1) | DE69624498T2 (es) |
| DK (1) | DK0858345T3 (es) |
| ES (1) | ES2183007T3 (es) |
| HK (1) | HK1015708A1 (es) |
| IT (1) | IT1277926B1 (es) |
| MX (1) | MX9801550A (es) |
| PT (1) | PT858345E (es) |
| RU (1) | RU2182014C2 (es) |
| WO (1) | WO1997009064A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025277A1 (en) * | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
| FR2812813B1 (fr) * | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
| IL161672A0 (en) * | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| FR2978964B1 (fr) | 2011-08-09 | 2015-02-20 | Conservatoire Nat Arts | Composition vaccinale anti-il-6 |
| WO2015024148A1 (zh) * | 2013-08-23 | 2015-02-26 | 中国科学院微生物研究所 | 异源动物细胞因子突变体疫苗 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2677654B1 (fr) | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
| US5338833A (en) * | 1992-07-23 | 1994-08-16 | The University Of North Carolina At Chapel Hill | Carboxy terminal IL-6 muteins |
| IT1263022B (it) * | 1992-11-06 | 1996-07-23 | Angeletti P Ist Richerche Bio | Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica. |
| IT1261787B (it) * | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
| AU6961796A (en) | 1995-09-12 | 1997-04-01 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
-
1995
- 1995-09-01 IT IT95RM000589A patent/IT1277926B1/it active IP Right Grant
-
1996
- 1996-08-22 EP EP96930345A patent/EP0858345B1/en not_active Expired - Lifetime
- 1996-08-22 MX MX9801550A patent/MX9801550A/es not_active IP Right Cessation
- 1996-08-22 PT PT96930345T patent/PT858345E/pt unknown
- 1996-08-22 DK DK96930345T patent/DK0858345T3/da active
- 1996-08-22 RU RU98105679/14A patent/RU2182014C2/ru not_active IP Right Cessation
- 1996-08-22 CN CNB961972955A patent/CN1138562C/zh not_active Expired - Fee Related
- 1996-08-22 AT AT96930345T patent/ATE226446T1/de not_active IP Right Cessation
- 1996-08-22 ES ES96930345T patent/ES2183007T3/es not_active Expired - Lifetime
- 1996-08-22 CA CA002229045A patent/CA2229045C/en not_active Expired - Fee Related
- 1996-08-22 KR KR1019980701561A patent/KR100279539B1/ko not_active IP Right Cessation
- 1996-08-22 AU AU69428/96A patent/AU703300B2/en not_active Ceased
- 1996-08-22 JP JP51104897A patent/JP3157837B2/ja not_active Expired - Fee Related
- 1996-08-22 DE DE69624498T patent/DE69624498T2/de not_active Expired - Fee Related
- 1996-08-22 WO PCT/IT1996/000164 patent/WO1997009064A1/en active IP Right Grant
-
1999
- 1999-03-09 HK HK99100962A patent/HK1015708A1/xx not_active IP Right Cessation
-
2000
- 2000-04-27 US US09/559,950 patent/US6706261B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT858345E (pt) | 2003-02-28 |
| CN1138562C (zh) | 2004-02-18 |
| JPH10511111A (ja) | 1998-10-27 |
| KR100279539B1 (ko) | 2001-02-01 |
| JP3157837B2 (ja) | 2001-04-16 |
| HK1015708A1 (en) | 1999-10-22 |
| DK0858345T3 (da) | 2003-02-24 |
| AU703300B2 (en) | 1999-03-25 |
| WO1997009064A1 (en) | 1997-03-13 |
| CA2229045C (en) | 2005-10-25 |
| DE69624498T2 (de) | 2003-06-18 |
| DE69624498D1 (de) | 2002-11-28 |
| EP0858345A1 (en) | 1998-08-19 |
| US6706261B1 (en) | 2004-03-16 |
| ATE226446T1 (de) | 2002-11-15 |
| RU2182014C2 (ru) | 2002-05-10 |
| AU6942896A (en) | 1997-03-27 |
| KR19990044321A (ko) | 1999-06-25 |
| IT1277926B1 (it) | 1997-11-12 |
| EP0858345B1 (en) | 2002-10-23 |
| CN1198098A (zh) | 1998-11-04 |
| ES2183007T3 (es) | 2003-03-16 |
| ITRM950589A0 (it) | 1995-09-01 |
| CA2229045A1 (en) | 1997-03-13 |
| ITRM950589A1 (it) | 1997-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY111196A (en) | Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
| CA2149329A1 (en) | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
| ATE407696T1 (de) | Vorbeugende- oder heilmittel zur behandlung von multipler sklerose, mit antagonistischen anti-il6-rezeptor antikörpern als wirkstoff | |
| DE3886046D1 (de) | Sich selbst stumpf machende nadeleinheit sowie diese aufweisende vorrichtung. | |
| CA2189250A1 (en) | Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels | |
| FI963101A0 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
| DE69132306D1 (de) | Menschlicher und Murin-Interleukin-5-Rezeptor | |
| EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
| PL309357A1 (en) | Pyrolopyrimidines as compounds acting as antagonists of corticotrophin releasing factor | |
| DE3584349D1 (de) | Lhrh-analoga, welche die anti-lhrh-antikoerper stimulieren und diese enthaltende vakzine. | |
| ES2083469T3 (es) | Peptido asociado a una latencia y utilizaciones del mismo. | |
| AU9064991A (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy | |
| WO2003063573A3 (en) | Method for treating diseases with omega interferon | |
| MX9801550A (es) | Uso de muteinas de citocinas de tipo silvestre como inmunogenos. | |
| WO1999024077A3 (en) | Compositions and methods for targeted delivery of biologically-active factors | |
| EP0815868A4 (en) | A CHINESE DRUG COMPOSITION FOR THE TREATMENT OF STOMULIC Ulcers AND THE PRODUCTION THEREOF | |
| DE59001121D1 (en) | Antacidatabletten. | |
| EP0795332A3 (en) | Medical use of gamma-interferon in interstitial lung diseases | |
| IT215307Z2 (it) | Dispositivo migliorato per la regolazione dell'inclinazione dello schienale e/o del sedile di seggiole in genere, in particolareper ufficio. | |
| WO2000063348A3 (fr) | Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie | |
| NO904041L (no) | Terapeutisk aktiv eksopolymer og fremgangsmaate for dens fremstilling. | |
| IT211865Z2 (it) | Dispositivo posizionatore perl'inclinazione di poggiatesta di poltrone, divani e simili. | |
| KR890002218U (ko) | 환자침대의 경사각도 조절용 핸들 | |
| IT8941689A0 (it) | Dispositivo per la regolazione dello schienale e del sedile di sedie e/o poltroncine. | |
| Silvera | Thy-1 (+) and Thy-1 (-) pulmonary fibroblast subpopulations synthesize inhibitors to interleukin-1, a pro-fibrotic cytokine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |